KURA

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2010, for Zeta Acquisition Corp. III. The registrant is a Delaware corporation organized as a "blank check" company and a "shell company" with no specific business plan other than to seek a business combination or merger with an unidentified target. The company has not conducted any active operations since its inception on November 16, 2007, and has generated no revenue. The filing notes a discrepancy in the request metadata regarding "Kura Oncology, Inc."; the provided text explicitly identifies the registrant as Zeta Acquisition Corp. III.

Key Financial Metrics

Note: The company has no debt other than notes payable to stockholders. Margins are not applicable due to zero revenue.

Material Changes vs. Prior Period

• Liabilities: Total liabilities increased by approximately 123% from $31,613 in 2009 to $70,389 in 2010. This increase was driven primarily by an additional $35,000 in notes payable from stockholders.
• Assets: Total assets increased by 126% to $29,398, reflecting a net increase in cash of $15,756.
• Net Loss: The net loss increased by approximately 12% to $22,395, attributed to legal, accounting, audit fees, and interest expense.
• Equity: The accumulated deficit grew from $(68,596) to $(90,991), resulting in a total stockholders' equity deficit of $(40,991).

Outlook, Risks, and Management Commentary

Going Concern: Management explicitly states that the company's ability to continue as a going concern is dependent on its ability to generate future profitable operations and/or obtain necessary financing. As of the report date, the company had no funds in its treasury aside from the cash balance reported and relies on related party advances.

Business Plan: The company intends to achieve long-term growth through a combination with a business. It has not identified any specific target and has not entered into any definitive agreements. Management anticipates incurring costs related to filing reports and investigating potential acquisitions.

Risks:

• Liquidity Risk: The company has no assurance it can satisfy cash requirements for the next twelve months without additional funding from stockholders or investors.
• Competition: The company faces intense competition from other "public shell" and "blank check" companies seeking business combinations.
• Management Resources: Officers and directors are engaged in outside business activities and devote limited time to the company. There are no full-time employees.
• Transaction Risk: Costs incurred in evaluating a target that is not acquired will result in a loss. Due diligence may be limited by financial resources.

Unusual Items: The company utilizes office space and equipment of its management at no cost. No compensation was paid to officers or directors during the period.

Investor Verification Checklist

• Identity Verification: Confirm the registrant is Zeta Acquisition Corp. III, not Kura Oncology, Inc., as the text provided does not match the metadata company name.
• Capital Adequacy: Verify the company's ability to fund operations for the next 12 months given the negative working capital and reliance on stockholder loans.
• Related Party Transactions: Review the terms of the $60,000 in notes payable to stockholders (6% interest, due on demand) and the lack of compensation to management.
• Shell Status: Acknowledge the company is a "shell company" with no operations, meaning investment value is entirely speculative based on a future merger.
• Stock Ownership: Note that as of March 31, 2011, there were only 4 holders of record, with management (John Pappajohn and Matthew P. Kinley) controlling 80% of the outstanding shares.